Reduced/VBN
mitogenic/JJ
stimulation/NN
of/IN
peripheral/JJ
blood/NN
mononuclear/JJ
cells/NNS
as/IN
a/DT
prognostic/JJ
parameter/NN
for/IN
the/DT
course/NN
of/IN
breast/NN
cancer/NN
:/:
a/DT
prospective/JJ
longitudinal/JJ
study/NN
./.

Immunosuppression/NN
has/VBZ
been/VBN
often/RB
associated/VBN
with/IN
the/DT
course/NN
of/IN
malignant/JJ
diseases/NNS
./.
=====
In/IN
the/DT
present/JJ
study/NN
,/,
the/DT
proliferation/NN
of/IN
peripheral/JJ
blood/NN
mononuclear/JJ
cells/NNS
(/(
PBMCs/NNS
)/)
in/IN
response/NN
to/TO
mitogenic/JJ
stimulation/NN
with/IN
phytohaemagglutinin/NN
(/(
PHA/NN
)/)
was/VBD
assessed/VBN
prospectively/RB
in/IN
90/CD
patients/NNS
with/IN
stage/NN
I-III/CD
breast/NN
cancer/NN
./.
=====
Whereas/IN
PHA-induced/JJ
proliferation/NN
of/IN
PBMCs/NNS
derived/VBN
from/IN
patients/NNS
with/IN
breast/NN
cancer/NN
preoperatively/RB
was/VBD
significantly/RB
decreased/VBN
when/WRB
compared/VBN
with/IN
data/NNS
obtained/VBN
in/IN
healthy/JJ
control/JJ
individuals/NNS
(/(
P/NN
</JJR
0.001/CD
)/)
,/,
the/DT
degree/NN
of/IN
the/DT
defect/NN
in/IN
PHA-induced/JJ
proliferation/NN
of/IN
PBMCs/NNS
depended/VBD
upon/IN
the/DT
tumour/NN
burden/NN
as/IN
manifested/VBN
by/IN
tumour/NN
size/NN
and/CC
axillary/NN
lymph/NN
node/NN
involvement/NN
(/(
P/NN
</JJR
0.003/CD
in/IN
each/DT
case/NN
)/)
./.
=====
PHA-induced/JJ
proliferation/NN
of/IN
PBMCs/NNS
dropped/VBD
significantly/RB
in/IN
patients/NNS
who/WP
received/VBD
adjuvant/JJ
chemotherapy/NN
consisting/VBG
of/IN
cyclophosphamide/NN
,/,
methotrexate/NN
and/CC
fluorouracil/NN
(/(
CMF/NN
)/)
after/IN
an/DT
observation/NN
period/NN
of/IN
6/CD
months/NNS
(/(
P/NN
</JJR
0.01/CD
)/)
,/,
but/CC
not/RB
in/IN
patients/NNS
under/IN
adjuvant/JJ
treatment/NN
with/IN
tamoxifen/NN
only/RB
./.
=====
After/IN
an/DT
additional/JJ
6/CD
months/NNS
(/(
i.e./FW
12/CD
months/NNS
after/IN
surgery/NN
)/)
,/,
PHA-induced/JJ
proliferation/NN
of/IN
PBMCs/NNS
was/VBD
similar/JJ
in/IN
patients/NNS
after/IN
adjuvant/JJ
chemotherapy/NN
with/IN
CMF/NN
and/CC
in/IN
those/DT
receiving/VBG
continued/JJ
adjuvant/JJ
tamoxifen/NN
treatment/NN
(/(
P/NN
>/JJR
0.1/CD
)/)
,/,
but/CC
in/IN
all/DT
patients/NNS
still/RB
significantly/RB
decreased/VBD
as/IN
compared/VBN
with/IN
healthy/JJ
controls/NNS
(/(
P/NN
</JJR
0.001/CD
)/)
./.
=====
When/WRB
data/NNS
obtained/VBN
preoperatively/RB
and/CC
after/IN
12/CD
months/NNS
were/VBD
compared/VBN
,/,
it/PRP
was/VBD
found/VBN
that/IN
out/RB
of/IN
23/CD
patients/NNS
whose/WP$
PBMCs/NNS
had/VBD
experienced/VBN
a/DT
drop/NN
in/IN
their/PRP$
PHA-induced/JJ
proliferation/NN
,/,
14/CD
(/(
61/CD
%/NN
)/)
had/VBD
developed/VBN
metastatic/JJ
disease/NN
within/IN
the/DT
subsequent/JJ
24/CD
months/NNS
(/(
i.e./FW
36/CD
months/NNS
after/IN
surgery/NN
)/)
./.
=====
In/IN
contrast/NN
,/,
out/RB
of/IN
59/CD
patients/NNS
whose/WP$
PBMCs/NNS
showed/VBD
an/DT
increase/NN
in/IN
their/PRP$
PHA-induced/JJ
proliferation/NN
within/IN
the/DT
first/JJ
12/CD
months/NNS
after/IN
surgery/NN
,/,
only/RB
one/CD
(/(
2/CD
%/NN
)/)
presented/VBD
with/IN
disease/NN
progression/NN
./.
=====
We/PRP
thus/RB
conclude/VBP
that/IN
PHA-induced/JJ
proliferation/NN
of/IN
PBMCs/NNS
derived/VBN
from/IN
patients/NNS
with/IN
breast/NN
cancer/NN
depends/VBZ
upon/IN
the/DT
tumour/NN
load/NN
and/CC
is/VBZ
a/DT
good/JJ
clinical/JJ
predictor/NN
for/IN
the/DT
further/JJ
course/NN
of/IN
the/DT
disease/NN
./.